Prior Authorization

Continuous Glucose Monitor (CGM)

Approval Criteria:

1. Ordering provider is an Illinois licensed physician specializing in Endocrinology, Diabetes, and Metabolism, or a nurse practitioner/physician assistant working under supervision of that specialist. Other prescribers must consult with a specialist in Endocrinology, Diabetes and Metabolism. That consult may take place through either an in-person or a telehealth visit. Documentation of that consultation will be required for prior approval requests from primary care physicians.

2. Only those CGMs meeting the below standards will be approved:

    - an alarm when glucose levels are outside the pre-determined range
    - capacity to generate predictive alerts in case of impending hypoglycemia
    - ability to transmit real time glucose values and alerts to patient and designated others.

Type 1 Diabetes:

- Patient has a diagnosis of Type 1 Diabetes.
- Patient requires an intensive insulin regimen (defined as: at least 1 per day dose of basal insulin and 2 or more shorter or rapid acting insulin injections per day, usually coinciding with meals), or utilizes an insulin pump.
- Prescriber attests that patient will be trained on the use of the requested CGM system.

Type 2 Diabetes:

- Patient has a diagnosis of uncontrolled Type 2 Diabetes Mellitus.
- Patient requires intensive insulin therapy (defined as: at least 1 per day dose of basal insulin and 2 or more rapid or shorter acting insulin injections per day, usually coinciding with meals).
- Patient has a recent history of emergency room visits or hospitalizations related to hypoglycemia, hyperglycemia or ketoacidosis.
- Prescriber attests that patient will be trained on the use of the requested CGM system.

Gestational Diabetes:

- Patient has a current diagnosis of gestational diabetes.
- Patient has suboptimal glycemic control which is likely to harm the mother or the fetus.
- Prescriber attests that patient will be trained on the use of the requested CGM system.

Exceptional Situations:

For patients with diabetes mellitus and specific situations that do not meet the above criteria, or in populations that CGM has not been well-studied, requests will be reviewed for medical necessity, and approved when appropriate, on a case-by-case basis.

Prior Approval Duration:

- Sensors and transmitters: 6-month approvals
- Receiver: approval up to once every 12 months, unless the CGM is connected to a patient's smart phone and a receiver will not be used.
- Gestational diabetes: approval for the remaining duration of that pregnancy and up to 12 months post-partum.

Renewal Criteria:

For continued approval, patient must have demonstrated:

- Adherence with the CGM and diabetes treatment.
- Improved HbA1c or time-in-range glucose values compared to baseline.
- Clinical benefit as determined by the prescriber.

References:

- American Diabetes Association. Glycemic targets: Standards of medical care in diabetes -2021. *Diabetes Care* . 2021; 44 (suppl 1): S73-S84. https://doi.org/10.2337/dc21-S006
- American Diabetes Association. Diabetes technology: Standards of medical care in diabetes -2021.*Diabetes Care* . 2021; 44 (suppl 1): S85-S99. https://doi.org/10.2337/dc21-S007
- American Diabetes Association. Children and adolescents: Standards of medical care in diabetes -2021. *Diabetes Care*. 2021; 44 (suppl 1): S180-S199. https://doi.org/10.2337/dc21-S013
- American Diabetes Association. Management of diabetes in pregnancy: Standards of medical care in diabetes -2021. *Diabetes Care*. 2021; 44(suppl 1): S200-S210. https://doi.org/10.2337/dc21-S014
- Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: The use of advanced technology in the management of persons with diabetes mellitus. *Endocrine Practice.* 2021;27(6): 505-537. https://doi.org/10.1016/j.eprac.2021.04.008
- Danne, T**,** Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care.* 2017; 40(12): 1631-1640. https://doi.org/10.2337/dc17-1600
- Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603. https://doi.org/10.2337/dci19-0028
- Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. *Endocr Pract*. 2016;22(4):231–61. https://doi.org/10.4158/EP151124.CS
- American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes – 2021. *Diabetes Care*. 2021;44 (suppl 1): S111-S124. https://doi.org/10.2337/dc21-S009
- Hirsch IB, Farkas-Hirsch R, Skyler JS. Intensive insulin therapy for treatment of Type 1 diabetes. *Diabetes Care.* 1990:13(12):1265-83. https://doi.org/10.2337/diacare.13.12.1265
- Centers for Medicare and Medicaid Services. Local coverage determination (LCD). Glucose monitors. CMS.gov. Updated 5.26.2021. Accessed on September 8, 2021. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822